Gliflozin: A Revolution in Heart Failure Treatment

Sometimes the greatest revolutions are born by chance, that's exactly what happened with gliflozins., a class of drugs created with a very specific purpose: to help diabetic patients control their blood sugar. The mechanism was simple, almost disarmingly simple: blocking a protein in the kidneys called SGLT2, which normally reclaims sugar from filtered blood, thus forcing the body to eliminate it through urine.

But during the clinical trials something completely unexpected emerged.Researchers began to notice benefits that had nothing to do with diabetes. The graphs were clear: these drugs were protecting the heart remarkably well and were working even in patients who didn't have diabetes.

Two landmark studies, DAPA-HF and EMPEROR-Reduced, have demonstrated a dramatic reduction in the risk of worsening heart failure and cardiovascular death.The evidence was such that within a very short time, gliflozins became the “fourth pillar” of heart failure therapy, joining drugs used for decades such as ACE inhibitors, beta-blockers, and mineralocorticoid antagonists.

The 2021 European guidelines assigned SGLT2 inhibitors a Class I recommendation, the highest level of scientific evidence.A recognition that changed clinical practice worldwide. The real revolution was yet to come. For decades, approximately half of all people with heart failure and normal heart pumping power—so-called "preserved heart failure"—had no truly effective treatment. These were patients whose hearts contracted well but were too stiff to fill with blood properly. A huge problem, for which there simply were no effective solutions.

The EMPEROR-Preserved and DELIVER studies demonstrated for the first time a clear benefit in these patients., making gliflozins the first and still only class of drugs effective in this category. Summing up all available studies (called meta-analyses), these drugs show a nearly 25% reduction in the risk of death from cardiovascular causes and new hospitalization for heart failure.

A quarter less risk: a simply enormous figure in this field.One of the most important discoveries concerns the speed of action of these drugs. Significant clinical benefit was achieved very early: as early as 28 days for dapagliflozin in the DAPA-HF study and as early as 18 days for empagliflozin in the EMPEROR-Preserved study. This speed is crucial in the so-called "vulnerable period," those first months after a heart failure hospitalization when the risk of death increases. Studies such as EMPULSE and DAPA ACT HF-TIMI 68 have shown that early initiation of SGLT2 inhibitor therapy during acute heart failure hospitalization produces significant benefits, so much so that the 2023 update of the ESC guidelines recommends initiation and rapid titration of therapy before discharge.

The benefits of gliflozins extend far beyond the heart. Studies such as CREDENCE, DAPA-CKD, EMPEROR-Reduced, and EMPA-KIDNEY have all confirmed a powerful protective effect on kidney function, making these drugs the most effective available for this purpose. The most interesting finding is that the earlier treatment is started, the longer the onset of end-stage renal disease is delayed, with an estimated delay of about 26 years if treatment is started with only mildly impaired kidney function. These aren't just numbers: they are years of life gained, years in which a patient can avoid dialysis.

How do gliflozins produce all these benefits? The full mechanism of action is still being studied, but scientists have identified several effects: reduction of fluid overload, anti-inflammatory effects, improved energy, and reduced nervous system activation. These mechanisms work synergistically to protect the heart and kidneys. Research continues, and the latest chapter in this story is even more surprising. Recent studies, including a retrospective study of over 95.000 patients and the prospective EMPACARD-PILOT study, suggest that gliflozins may prevent heart damage induced by chemotherapy, with an 88% reduction in the incidence of cardiac dysfunction in patients treated with doxorubicin, a common drug in cancer therapy. This is a frontier yet to be fully explored and, above all, confirmed, but incredibly promising for cancer patients, who often face the difficult dilemma of curing their cancer and protecting their heart.

Despite all this overwhelming evidence, there is still a problemTherapeutic inertia. Too often, these lifesaving drugs are not prescribed quickly enough, especially in high-risk, acutely ill patients. In Italy, at least, gliflozins have become prescription drugs Without the need for a treatment plan, this greatly simplifies their prescription and accessibility. This is an important step towards ensuring that these benefits reach all patients who need them.

The history of gliflozins teaches us something fundamentalScience can yield unexpected discoveries that radically transform our understanding of disease. A drug developed for diabetes has proven lifesaving for millions of people with heart failure and kidney disease.

For patients and their families, understanding the science behind these therapies isn't just a matter of curiosity. It means having the right tools to communicate with doctors and actively participate in decisions about their own health. Ultimately, it means looking to the future not only with hope, but with the certainty that the course of these conditions can truly be changed for the better.